Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient

@article{Piscolla2013ReboundAF,
  title={Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient},
  author={Elisa Piscolla and Bahia Hakiki and Luisa Past{\`o} and Lorenzo Razzolini and Emilio Portaccio and Maria Pia Amato},
  journal={Journal of Neurology},
  year={2013},
  volume={260},
  pages={1675-1677}
}
Fingolimod is an oral agent approved for the treatment of relapsing-remitting Multiple Sclerosis (RRMS). Data about a possible reactivation of disease activity after Fingolimod withdrawal are limited [1–3]. We report a case of clinical and magnetic resonance (MR) rebound after Fingolimod discontinuation in a 19-year-old woman with pediatriconset MS (POMS). Case-report: A 19-year-old woman was diagnosed as RRMS in February 2004, when she was 11. Two relapses occurred before initiation of… CONTINUE READING
10 Citations
8 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

scientific rationale, history and novel treatment paradigms

  • A Awad, Stüve O Cyclophosphamide in multiple sclerosis
  • Ther Adv Neurol Disord 2(6):50–61 J Neurol
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…